MedTrace Logo

Reiki for the Management of Neuropathic Pain

NCT02328703 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2017-05-30

No results posted yet for this study

Summary

This is a prospective, randomized, double-blind, placebo-controlled, repeated measures study with intention-to-treat that involves exposure to Reiki therapy or a placebo control intervention for a total of six treatments, three treatments per week for two weeks, with a 2-week follow-up for the decrease of neuropathic pain in extremity trauma.

Conditions

  • Neuropathic Pain
  • Amputation, Traumatic

Interventions

OTHER

Reiki Therapy

Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.

Sponsors & Collaborators

  • Defense and Veterans Center for Integrative Pain Management

    collaborator OTHER

  • University of Pennsylvania

    collaborator OTHER

  • Walter Reed National Military Medical Center

    collaborator FED

  • Fort Belvoir Community Hospital

    lead FED

Principal Investigators

  • MeLisa Gantt, PhD · Fort Belvoir Community Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02328703 on ClinicalTrials.gov